History | Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | Guidance | NICE

History

Documents created during the development process.

Expected publication

Register of interests (PDF 288 KB)

Published:

19 April 2023
Equality Impact Assessment (Guidance development) (PDF 146 KB)

Published:

19 April 2023

Final evaluation determination

Final evaluation determination
Committee papers (PDF 7.54 MB)

Published:

16 March 2023
Public committee slides (PDF 928 KB)

Published:

16 March 2023
Final evaluation determination document Equality Impact Assessment (PDF 146 KB)

Published:

16 March 2023
Final evaluation determination document (PDF 240 KB)

Published:

16 March 2023

Invitation to participate

Final scope (PDF 172 KB)

Published:

09 June 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 442 KB)

Published:

09 June 2022
Equality impact assessment (Scoping) (PDF 126 KB)

Published:

09 June 2022
Final stakeholder list (PDF 210 KB)

Published:

09 June 2022

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 189 KB)

Published:

22 April 2022
Draft matrix post referral (PDF 209 KB)

Published:

22 April 2022